[ad_1]
Novavax, Inc. The shares (NASDAQ: NVAX) are trading up 8.4% to $ 242.67 on an ongoing basis after the company on Wednesday announced an agreement with the European Commission to purchase up to $ 200 million. doses of his COVID-19 vaccine.
Shares of Novavax have been trading up 32.5% in the past five sessions amid continued concerns over the delta variant of COVID-19, which have increased vaccine stocks.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on providing new products that prevent a wide range of diseases. Novavax is working with its 100% Swedish subsidiary to produce candidate vaccines to address threats from known and emerging diseases.
Novavax has a 52 week high of $ 331.68 and a 52 week low of $ 76.59.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source link